AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GEVG | 21.87 | -0.03 | -0.12% |
| Leverage Shares 2X Long GEV Daily ETF (GEVG) | |||
| SPSK | 17.57 | -0.11 | -0.62% |
| SP Funds Dow Jones Global Sukuk ETF (SPSK) | |||
| IJS | 130.22 | -1.52 | -1.15% |
| iShares S&P Small-Cap 600 Value ETF (IJS) | |||
| IWMW | 38.07 | -0.45 | -1.17% |
| iShares Russell 2000 BuyWrite ETF (IWMW) | |||
| DFMC | 58.01 | -0.72 | -1.23% |
| U.S. Micro Cap Portfolio ETF (DFMC) | |||
A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To ABCL | 1D Price Change % | ||
|---|---|---|---|---|
| ABCL | 100% | -0.08% | ||
| RXRX - ABCL | 59% Loosely correlated | +2.02% | ||
| ABSI - ABCL | 56% Loosely correlated | +9.06% | ||
| VCYT - ABCL | 56% Loosely correlated | +4.43% | ||
| CRSP - ABCL | 54% Loosely correlated | +1.20% | ||
| EDIT - ABCL | 51% Loosely correlated | +3.18% | ||
More | ||||
ABCL saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 75 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 82%.
The Moving Average Convergence Divergence (MACD) for ABCL just turned positive on September 22, 2026. Looking at past instances where ABCL's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
Following a +11.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 205 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 120 of 155 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The 10-day RSI Indicator for ABCL moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 23 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
ABCL broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.575) is normal, around the industry mean (25.951). P/E Ratio (11.976) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (436.793).
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.